Jefferies reiterates Salesforce stock rating citing Agentforce momentum By Investing.com

Jefferies reiterated a Buy rating on Salesforce and maintained a $250 price target ahead of May 27 earnings, citing 9% partner-expectation growth, improving Agentforce adoption, and in-line first-quarter estimates for 12.5% revenue growth and 14% cRPO growth. Offseting positives include 25% of partners seeing seat reductions at renewal and rising concern that Anthropic is the biggest AI threat. Salesforce shares rose 1.3% as sector sentiment improved, with options implying a 7.9% move on earnings day.

Analysis

CRM is still being priced like a durable compounder, but the more interesting signal is that AI adoption is already creating a near-term monetization headwind before it becomes a growth tailwind. The rise in seat reductions at renewal suggests customers are using agentic tools to substitute for low-value user seats, which can compress net expansion even if headline product adoption looks healthy. That creates a two-speed setup: product enthusiasm can lift sentiment into earnings, while the actual financial payback likely lags by several quarters.

The competitive risk is less about a single vendor and more about a broader redistribution of workflow ownership. If buyers increasingly route simple service/sales tasks into AI-native layers, CRM risks becoming the system of record while the value capture migrates upward to model and orchestration providers. That is bullish for infrastructure beneficiaries, but it pressures adjacent application vendors whose pricing power depends on per-seat economics.

For the next 1-2 quarters, the key catalyst is not just revenue growth but RPO quality and renewal behavior. If the market sees continued seat compression without offsetting net-new module attach, the multiple can de-rate quickly even on in-line results. Conversely, if management can show that Agentforce is driving broader platform consolidation rather than cannibalizing seats, the stock likely re-rates back toward the upper end of the current analyst band.

The contrarian view is that consensus may be overestimating near-term AI monetization and underestimating how long it takes to translate product hype into durable ARR per customer. The setup looks constructive tactically into earnings, but the medium-term risk is that AI adoption becomes a customer bargaining lever rather than a growth engine. That makes the stock vulnerable to any guide that emphasizes usage growth without corresponding evidence of pricing retention or expansion in higher-value clouds.

Key Decisions for Investors

• Trade CRM into earnings with a defined-risk bullish structure: buy the May/June call spread or a call spread into the event, targeting a 1-2 month horizon where sentiment can outrun fundamentals; cap downside if management disappoints on renewal metrics.
• After the print, fade strength if seat-reduction commentary persists: short CRM on any post-earnings pop above the implied move, with a 2-4 week horizon and a stop on evidence that net retention is stabilizing.
• Consider a pair trade long DDOG / short CRM for 1-3 months if the market continues rewarding AI infrastructure over AI-enabled applications; DDOG has clearer usage-based monetization while CRM faces seat pressure.
• Buy CRM only on a pullback tied to guidance conservatism, not on hype alone; use a staggered entry over 2-6 weeks and require confirmation that Agentforce is increasing attach rates rather than replacing seats.
• Watch for a catalyst-driven de-risking point: if renewal seat reductions worsen next quarter, reduce CRM exposure by 30-50% because the market will likely re-rate the stock before headline revenue deterioration shows up.